ANGIOTENSIN-CONVERTING ENZYME - CLINICAL-APPLICATIONS AND LABORATORY INVESTIGATIONS ON SERUM AND OTHER BIOLOGICAL-FLUIDS

被引:85
作者
BENETEAUBURNAT, B
BAUDIN, B
机构
[1] Laboratoire de Biochimie A (Dr J. GIBOUDEAU), Hospital Saint-Antoine, 75571, Paris, Cedex 12, 184, rue du Fbg St-Antoine
关键词
ANGIOTENSIN I-CONVERTING ENZYME; ACE ACTIVITY; ACE INHIBITORS; ENOLOTHELIUM; SARCOIOLOSIS;
D O I
10.3109/10408369109106868
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Angiotensin I-converting enzyme (ACE) is a peptidyldipeptide hydrolase that is located mainly on the luminal surface of vascular endothelial cells but also in cells derived from the monocyte-macrophage system. Physiologically, ACE is a key enzyme in the renin-angiotensin system, converting angiotensin I into the potent vasopressor angiotensin II and also inactivating the vasodilator bradykinin. Increased serum ACE activity (SACE) has been reported in pathologies involving a stimulation of the monocytic cell line, primarily granulomatous diseases. Sarcoidosis is the most frequent and the better studied of these diseases; high SACE is not only a well-established marker for the diagnosis but is also a useful tool for following its course and evaluating the effect of therapy. SACE can also be increased in nonsarcoidotic pulmonary granulomatous diseases such as silicosis and asbestosis, in extrathoracic granulomatous pathologies such as Gauchers disease and leprosis, and, to a lesser extent, in nongranulomatous disorders such as hyperthyroidism or cholestasis. On the other hand, monitoring sarcoidosis obviates the measurement of ACE activity in other biological fluids, e.g., bronchoalveolar and cerebrospinal fluids, in the search of a locoregional dissemination or dissimulation of the disease. Decreased SACE has been reported in vascular pathologies involving an endothelial abnormality, e.g., deep vein thrombosis, and in endothelium dysfunctions related to the toxicity of chemo- and radiotherapy used in cancers, leukemias, and hematopoietic or organ transplantations. SACE is also of interest for monitoring arterial hypertension treated with specific synthetic ACE inhibitors. These various reasons for determining ACE activity have led to the development of numerous methods. The most widely used is the spectrophotometric assay using hippuryl-histidyl-leucine as substrate. Fluorimetric and radiochemical assays using both classic and novel substrates have been proposed, but they are time consuming, require special apparatus, and are not suited to automation. Kinetic spectrophotometry of furylacryloyl-phenylalanylglycyl-glycine hydrolysis is now used extensively because it is easy to automatize. Efforts are now required to standardize one or more of these assays. Indeed, "normal" plasma values differ not only according to the substrate, but also to the method of determination and to sex and age.
引用
收藏
页码:337 / 356
页数:20
相关论文
共 146 条
[1]  
AINSLIE GM, 1985, Q J MED, V55, P253
[2]  
ALHENCGELAS F, 1983, J LAB CLIN MED, V101, P83
[3]  
ASHTON JH, 1984, J PHARMACOL EXP THER, V232, P602
[4]  
BAKHLE YS, 1974, HDB EXPTL PHARMACOLO, V37, P41
[5]  
BAUDIN B, 1990, J CLIN CHEM CLIN BIO, V28, P857
[6]   MOLECULAR-WEIGHT AND SHAPE OF ANGIOTENSIN-I CONVERTING ENZYME - A NEUTRON-SCATTERING STUDY [J].
BAUDIN, B ;
TIMMINS, PA ;
DROUET, L ;
LEGRAND, Y ;
BAUMANN, FC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 154 (03) :1144-1150
[7]   INVITRO INTERACTIONS BETWEEN RAMIPRILAT AND ANGIOTENSIN-I CONVERTING ENZYME IN ENDOTHELIAL-CELLS [J].
BAUDIN, B ;
DROUET, L .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 14 :S37-S42
[8]  
BAUDIN B, 1988, TECHNOLOGIES PURIFIC, V3, P337
[9]  
BAUDIN B, 1990, 20TH M FED EUR BIOCH
[10]  
BAUGHMAN RP, 1983, AM REV RESPIR DIS, V128, P631